Oxford University Announces Safety of AstraZeneca Vaccine.

source: torstensimon from Pixabay

The third phase of trials showed that the drug is safe and effective in 79% of cases against symptomatic coronavirus disease. The vaccine protects 100% against the severe course of COVID-19.

Oxford University published results of the third phase of clinical trials of a coronavirus vaccine, which it developed jointly with the British-Swedish pharmaceutical company AstraZeneca.

The studies took place in the United States, Chile, and Peru, involving more than 32 thousand volunteers of all age groups. The subjects were given either two doses of the drug or a placebo four weeks apart. The report said These data prove that the vaccine is 100% efficient against severe or critical illness and 79% effective against symptomatic COVID-19. These data show that the vaccine is 79% effective against symptomatic COVID-19 and 100% effective against severe or critical illness," the report said.

According to the University of Oxford, the results also show the safety of the drug, which complements previous data from studies in the UK, Brazil, and South Africa, as well as the vaccination campaign in the United Kingdom.

The vaccine from AstraZeneca has shown a high level of protection against COVID-19 in many countries and among people of different ages, said Professor Sarah Gilbert, one of the drug developers. We hope that it will make even more comprehensive use of the vaccine, from their references to the BBC. According to Gilbert, there have always been cases of people having health problems after vaccination, but this does not mean that it was the drug that caused them.

In March, countries began to announce the complete or partial cessation of the AstraZeneca vaccine amid reports of blood clots in some vaccinated patients and several deaths. The European Medicines Agency (EMA) said there were 30 cases of thromboembolism among 5 million people who received a vaccine dose. AstraZeneca, in turn, said that as of March 8, 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism were registered in the UK and EU countries, out of 17 million people who were vaccinated with its vaccine. The company stressed that there is no evidence that it was the use of the vaccine that led to this. The company previously noted that the vaccine is "well-tolerated.